SUMMARY Intragastric pH was monitored during 24 hours in eight volunteers with duodenal ulcer disease in remission, while on placebo, cimetidine 400 mg bd, pirenzepine 50 mg bd, cimetidine 400 mg bd + pirenzepine 50 mg bd, cimetidine 200 mg bd + pirenzepine 25 mg bd. The control of intragastric acidity during the 24 hour period by the combination of low dose cimetidine and pirenzepine was significantly better than with cimetidine, or pirenzepine alone in full dosage. This difference was most apparent after breakfast but was still present after lunch when cimetidine had no significant effect. Combination treatment is a logical approach when continuous control of intragastric acidity is needed, but a three times daily regimen will be necessary to cover the 24 hours.
Pirenzepine is known to inhibit gastric acid secretion induced by a variety of stimuli, including penltagastrinl, insulin,' 2 sham-feeding3 and a peptone meal. 4 Pirenzepine is thought to inhibit selectively the type I muscarinic receptor located in vagal ganglia.5 Cimetidine, however, inhibits gastric acid secretion by antagonism of parietal cell H2 receptors. 6 Combined administration of the two drugs might therefore be expected to result in a greater degree of acid inhibition than with either alone. Londong et at4 demonstrated this effect after intravenous administration of the drugs using in vivo titration and a peptone meal stimulus. As the therapeutic effect of cimetidine and pirenzepine in combination is being assessed in the treatment of duodenal ulcer in clinical trial we considered it important to evaluate the effects on intragastric acidity throughout a 24 hour period using conventional oral dosages. (mean of hourly readings) for each subject were compared between treatment groups. Area under the hydrogen ion activity curve was used to compare the effect of the different treatments during the four hours after meals. The Wilcoxon's rank sum test was used to test for significance, comparing by rank the data for each subject on different treatments. For descriptive purposes only the data have been displayed graphically as mean values with standard errors of the mean (SEM).
Methods

Results
Mean hourly hydrogen ion activity (mmol/l) for each treatment group over the 24 hour period has been displayed in Figure 1 .
Pirenzepine alone had no significant effect on intragastric acidity and did not change the 24 hour H+ activity as compared with placebo ( Fig. 2) . Cimetidine alone was significantly better than placebo or pirenzepine, resulting in a 26% decrease in mean hourly hydrogen ion activity (p<005). Both high and low dose combinations produced a further lowering of intragastric acidity. The effects of both combinations were similar with the low dose combination being significantly better than either pirenzepine or cimetidine alone in twice the dosage (p<O0O5). The hydrogen ion activity profile for this dose has been included in Figure 2 PL P50 C400 C400 C200 P50 P25 Treatment Fig. 3 Area under the hydrogen ion activity curve after breakfast (0800 to 1200 h) and lunch (1300 to 1700 h) for each treatment group. (mean ±SEM, n=8).
high dose combination was significantly better than pirenzepine alone but did not quite reach statistical significance when compared with cimetidine alone.
The effect of each of the regimens on the meal periods is shown as mean area under the hydrogen ion activity curve after breakfast and lunch in Figure  3 . Pirenzepine alone had no demonstrable effect after either meal. Significant inhibition occurred after breakfast after cimetidine alone (p<005), but no effect was seen after lunch. Both combinations, however, were better at decreasing meal stimulated acidity than either cimetidine or pirenzepine alone after both breakfast and lunch (p<001). Between the hours of 1700 and 2300 no drug effects were apparent. Significant inhibition of nocturnal secretion (between 2300 and 0800) was seen with cimetidine alone and with both drug combinations (p<0-01 vs placebo and pirenzepine) but no statistically significant difference was seen between cimetidine alone and the combinations (Fig. 4) .
No subject complained of adverse effects during this study and no significant changes were seen on haematological or biochemical screening. acidity.9 Pirenzepine is no exception to this"' which is confirmed by our data. We have also confirmed the significant effect of cimetidine given alone," and shown that the two drugs given in combination produce a further decrease in hydrogen ion activity that is greater than can be expected by an additive effect, particularly as this is seen when the combination doses are halved. This synergism is most apparent after a meal stimulus and is even seen five to nine hours after drug administration, when cimetidine alone has no effect.
At night little additional benefit is seen for either combination over cimetidine alone. This is not surprising in this group of duodenal ulcer subjects who respond well to cimetidine, in contrast with a group of non-responders whose nocturnal acid output was little decreased by cimetidine alone, but showed a significant lowering on cimetidine 1 g daily (200 mg tds, 400 mg nocte) combined with atropine 4-8 mg daily (1-2 mg qds with food).'2 A previous study" had shown that the addition of atropine 2-4 mg/day to cimetidine 1 g/day failed to reduce further 24 hour intragastric acidity in duodenal ulcer patients who had responded to cimetidine. This dose produced no side effects but the higher dose'2 caused anticholinergic symptoms in all seven subjects studied, in contrast with our experience with pirenzepine where no side effects were encountered. This is in keeping with the gastro-selective (Ml) 
